Given the lack of efficacy of disease-modifier therapies in patients with dementia, scientific interest has grown on individuals at-risk for AD, that is, showing the earliest signs of neuropathological events (i.e., amyloid or tau pathology) in the absence of AD-related cognitive symptoms [20]. This evidence concerns the gene MAPT and Alzheimer disease.